<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="78594">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02082301</url>
  </required_header>
  <id_info>
    <org_study_id>MH-IRB12-00581</org_study_id>
    <nct_id>NCT02082301</nct_id>
  </id_info>
  <brief_title>Oral Glucose Tolerance Testing After Gestational Diabetes</brief_title>
  <official_title>Oral Glucose Tolerance Testing After Gestational Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MetroHealth Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centers for Disease Control and Prevention</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Loyola University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>MetroHealth Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an observation study of women with gestational diabetes. Subjects recruited undergo
      immediate postpartum diabetic screening prior to discharge. Post-partum screening for overt
      diabetes is repeated 6-12 weeks postpartum. The outcome of interest is the utility of an
      immediate post partum screen for overt diabetes compared to a traditional 6 week test.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>October 2012</start_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Primary outcome: sensitivity of immediate post partum screen</measure>
    <time_frame>Immediate post partum</time_frame>
    <description>2 hour fasting 75g OGTT immediately post partum. This is compared to a traditional 6 week post partum 75g OGTT for the sensitivity, positive and negative predictive value of the immediate post partum test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary outcome: physiology</measure>
    <time_frame>3 time points: antepatum, immediate postpartum, 6 weeks post partum</time_frame>
    <description>A small sub-cohort of women will undergo an additional 2 hour fasting 75g OGTT in the third trimester with measurements of insulin, cytokines, lipids.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Gestational Diabetes</condition>
  <condition>Pregnancy</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Gestational diabetes</arm_group_label>
    <description>Primary cohort is women with diagnosis of gestational diabetes without evidence of overt diabetes</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum for measurements of insulin, markers of inflammation
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Primary cohort is obtained from a pregnant population at two academic medical centers.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Singleton pregnancy

          -  Gestational diabetes

        Exclusion Criteria:

          -  Multiple gestations

          -  pre-pregnancy diabetes
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thaddeus Waters, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Loyola University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MetroHealth Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <lastchanged_date>April 28, 2015</lastchanged_date>
  <firstreceived_date>March 6, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>MetroHealth Medical Center</investigator_affiliation>
    <investigator_full_name>Ted Waters</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes, Gestational</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
